IDYA Q3'26 Earnings: revenue estimate is 7.58M USD

What happened

IDEAYA Biosciences is scheduled to report its Q3’26 results on November 10, with disclosure expected at 7:00 a.m. ET. The article lists estimated revenue of 7.58 million USD and anticipated earnings per share, a company’s profit or loss divided by its shares.

Confirmed

Global impact / market context

The estimates give investors a benchmark for judging the company’s reported revenue and per-share loss. If actual results differ, the size of that gap could influence expectations for the business and its cash needs, although the article provides no forecast of cash balances or spending.

Analyst inference

The article provides an estimated revenue figure but no Q3’26 reported results or market reaction. Earlier quarterly reported revenue varied, so investors cannot treat the estimate as a confirmed trend; actual results could influence views of the company’s ability to generate revenue.

Analyst inference

What to watch

1. Check the November 10 release for reported revenue and compare it with the article’s 7.58 million USD estimate to see whether sales matched expectations. Proposed
2. Review the reported earnings per share, meaning profit or loss divided by shares, against the stated expectation; the article gives no reported figure yet. Proposed
3. Look for any company explanation of revenue changes and spending, since those details could help investors judge whether future operations need additional funding. Analyst inference

Evidence

• Original source link unavailable